EXPAREL (Bupivacaine) Patent Expiration, LOE Window & CMS Spending

EXPAREL (Bupivacaine) by Pacira: FDA Orange Book core substance LOE 2044-07-02, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPacira
FDA Application & PathwayN022496 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2044-07-02
Last Listed Patent or Exclusivity Date2044-07-02
Orange Book Patents (*PED Extensions)52 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 21.4% 2-yr change)